Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens

Contraception

Volumn 77, Issue 3, 2008, Pages 162-170

  Vandever, Misty A ^a   Kuehl, Thomas J ^a   Sulak, Patricia J ^a   Witt, Iris ^a   Coffee, Andrea ^a   Wincek, Thomas J ^a   Reape, Kathleen Z ^b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Duramed Research Inc   (United States)

Author keywords

Estradiol; Gonadotropins; Hormone withdrawal symptoms; Oral contraceptive pills; Ovarian follicles; Ovarian suppression

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; PLACEBO; SEASONIQUE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; HYPOPHYSIS OVARY SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUATION; MOOD CHANGE; NORMAL HUMAN; ORAL CONTRACEPTION; OVARY; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVULATION INHIBITION; PELVIS PAIN SYNDROME; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; TRANSVAGINAL ECHOGRAPHY;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INHIBINS; LEVONORGESTREL; LUTEINIZING HORMONE; OVARIAN FOLLICLE; PITUITARY GLAND; PROSPECTIVE STUDIES;

EID: 39149097511     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.11.005     Document Type: Article

References (14)

1. Willis S.A., Kuehl T.J., Spiekerman A.M., and Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74 (2006) 100-103
2. Sullivan H., Furniss H., Spona J., and Elstein M. Effect of 21-day and 24-day oral contraceptives decreases follicular development. Fertil Steril 72 (1999) 115-120
3. Schlaff W.D., Lynch A.M., Hughes H.D., Cedars M.I., and Smith D.L. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol 190 (2004) 943-951
4. VanHeusden A.M., and Fauser B.C. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 59 (1999) 237-243
5. Sulak P.J., Scow R.D., Preece C., Riggs M.W., and Kuehl T.J. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
6. Coffee A., Kuehl T.K., Willis S.A., and Sulak P.J. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 195 (2006) 1311-1319
7. Kuehl T.K., Speikermann M., Willis S.A., Coffee A., and Sulak P.J. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen. J Reproduct Med (2007) (in press)
8. Sulak P.J., Willis S.A., Kuehl T.J., Coffee A., and Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47 (2007) 27-37
9. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73 (2006) 229-234
10. Anderson F.D., Hait H., and the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68 (2003) 89-96
11. Juengel J.L., and McNatty K.P. The role of proteins of the transforming growth factor-b superfamily in the intraovarian regulation of follicular development. Hum Reprod Update 11 (2005) 144-161
12. Klein N.A., Illingworth P.J., Groome N.P., McNeilly A.S., Bataglia D.E., and Soules M.R. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 81 (1996) 2742-2745
13. Killick S.R., Fitzgerald C., and Davis A. Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 179 (1998) S18-S24
14. Sulak P, Kuehl T, Coffee A, Vandever M, Reape K. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Obstet Gynecol 2007;109(4 Suppl):102S.